Description
SITAGIL M 50/500 tablets offer a powerful dual-action approach to managing Type 2 Diabetes Mellitus. Each tablet combines 50mg of Sitagliptin (a DPP-4 inhibitor) and 500mg of Metformin (a biguanide), working synergistically to provide comprehensive blood glucose control. Sitagliptin enhances your body’s natural ability to produce insulin and reduce liver glucose production, particularly when blood sugar levels are high. Metformin complements this action by decreasing glucose absorption from the gut, reducing glucose output from the liver, and improving insulin sensitivity in the body’s cells. This combined therapy effectively lowers both fasting and post-meal blood sugar levels, significantly improving HbA1c and reducing the risk of long-term diabetes complications such as kidney damage, vision loss, and cardiovascular issues. SITAGIL M 50/500 is typically used as an adjunct to diet and exercise, or when monotherapy is insufficient, and should be taken with meals as directed by your healthcare professional.
